ECO Animal Health Group sales up 46% at £105.6m

ECO Animal Health Group plc (LON:EAH) has announced its results for the year ended 31 March 2021.

HIGHLIGHTS

Financials

· Sales up 46% at £105.6m (2020: £72.1m)

· Gross margin increased to 51% (2020: 46%)

· Profit before tax increased significantly to £20.3m (2020 restated: £6.1m)

· Earnings per share increased significantly to 12.08p (2020 restated: 5.77p)

· Cash generated from operations significantly stronger at £15.8m (2020: £5.5m)

· Net cash at the end of the period £19.5m (2020: £9.8m)

· New product development expenditure 17% lower at £9.1m (2020: £10.9m)

· Dividend re-introduced – 1p per share (2020: Nil)

Operations

· Aivlosin® demand increased by 44% led by

o  Rapid recovery & return to profitability in China as swine herds rebuilt following worst effects of African Swine Fever (ASF)

o  Strong growth in USA amid domestic demand & strengthening exports

o  Strong export driven growth in Brazil

· Aivlosin® water soluble formulation approval in pigs for M. hyopneumoniae granted in USA, Canada & EU

· First vaccine licence approval in Brazil

· Two worldwide exclusive research partnerships signed to develop & licence novel vaccines for pigs against Porcine Respiratory & Reproductive Syndrome virus (PRRSV)

· Business logistics, volumes and access uninterrupted during COVID-19 remote working

Marc Loomes, CEO of ECO Animal Health Group plc, commented: “These excellent results reflect the strong recovery in selected key markets which, together with the adaptability and innovation shown by our employees has delivered a record result during a year of formidable operational challenges arising from macroeconomic events.  We are excited about the progress within our new product development programmes, with previous announcements demonstrating the potential of our in-house science and external collaborations.  This year has had a solid start, we carefully monitor the demand for our products and recognise the easing in China, but remain confident of a successful out-turn for the year.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

ECO Animal Health ECOVAXXIN® trademark approved by the EU

ECO Animal Health Group plc (LON:EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, has announced that the ECOVAXXIN® trademark has been approved by the European

ECO Animal Health Group plc

ECO Animal Health completes sale of freehold properties

ECO Animal Health Group plc (LON:EAH) has announced that on 5 January 2024 the Company completed the sale of its freehold property in New Malden, Surrey.  This was the former registered office of the Company and following

ECO Animal Health Group plc

ECO Animal Health to host two Capital Markets events

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it will be hosting two Capital Markets events focused on progress and

ECO Animal Health Group plc

ECO Animal Health Group Retail Investor Presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will be hosting a Capital Markets Day presentation for retail investors focusing on progress

ECO Animal Health Group plc

ECO Animal Health AGM to be held on Thursday 7 September 2023

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that the Company is today posting to shareholders notice of the Company’s Annual

ECO Animal Health Group plc

ECO Animal Health Group revenue ahead of market expectations

ECO Animal Health Group plc (LON:EAH) have today provided final results for the year ended 31 March 2023. HIGHLIGHTS Financial ·      Revenue and adjusted EBITDA ahead of market expectations ·      Group sales increased by 4% to £85.3m, driven primarily